TrialBritish journal of haematology2017

Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.

Jeff P Sharman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.